Denali Therapeutics to Sell FDA Priority Review Voucher for $195M
SOUTH SAN FRANCISCO, Calif., June 18, 2026 Denali Therapeutics Inc. announced it has entered into a definitive agreement to...
Denali Therapeutics
Advertisement
Biogen, Denali End BIIB122 Parkinson’s Program
CAMBRIDGE, Massachusetts and SOUTH SAN FRANCISCO, California, May 21, 2026 Biogen Inc. and Denali Therapeutics Inc. announced that the...
Denali Therapeutics Regains DNL593 Rights for FTD
SOUTH SAN FRANCISCO, Calif., April 3, 2026 Denali Therapeutics Inc. announced it has regained full global rights to its...
FDA Approves AVLAYAH for Hunter Syndrome Treatment
SOUTH SAN FRANCISCO, Calif., March 25, 2026 In a landmark regulatory milestone, Denali Therapeutics announced that the U.S. Food...
Advertisement
